Blocknomi
Key Highlights Revolution Medicines shares skyrocketed 20% following breakthrough Phase 3 results showing daraxonrasib extended median survival beyond 12 months in pancreatic cancer patients—a first for this disease. The experimental…
Related articles
-
Grayscale Says Hyperliquid Could Become a DeFi Juggernaut
Bitcoin.com Published 28.05.2026 00:20
-
ERC-7943 author says institutions can’t play DeFi’s ‘pirate game’
Cointelegraph Published 28.05.2026 14:45
-
Bitcoin Vs. The S&P: How The Stock Market Predicts The BTC Bottom Before the Rally
Bitcoinist Published 27.05.2026 17:00
-
Samsung and SK Hynix Breach $1 Trillion Valuation — Forcing Fund Managers to Dump Shares
Blocknomi Published 29.05.2026 09:22
-
Strategy’s bitcoin sale sparks a $14 million betting chaos on Polymarket
CoinDesk Published 01.06.2026 14:49
-
LBank Joins Forces With RootData To Advance Scalability Of Crypto Trading Solutions
BlockchainReporter Published 03.06.2026 19:00
-
The Last Time Ethereum Did This Against Bitcoin, It Exploded Above $4,000
NewsBTC Published 02.06.2026 18:00
-
CFTC and Gemini Jointly Move to Vacate 2022 Consent Order After Enforcement Review
Blocknomi Published 28.05.2026 01:02